JP Morgan Chase
SMMT icon

JP Morgan Chase’s Summit Therapeutics SMMT Stock Holding History

JP Morgan Chase’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
68,169
+3,615
+6% +$64.1K ﹤0.01% 4624
2026
Q1 		$1.1M Sell
64,554
-2,868
-4% -$46.4K ﹤0.01% 4554
2025
Q4 		$1.18M Sell
67,422
-69,204
-51% -$1.3M ﹤0.01% 4491
2025
Q3 		$2.82M Sell
136,626
-69,481
-34% -$1.68M ﹤0.01% 3814
2025
Q2 		$4.39M Sell
206,107
-369,512
-64% -$8.43M ﹤0.01% 3275
2025
Q1 		$11.1M Buy
575,619
+436,038
+312% +$8.75M ﹤0.01% 2442
2024
Q4 		$2.49M Sell
139,581
-23,068
-14% -$447K ﹤0.01% 3981
2024
Q3 		$3.56M Sell
162,649
-1,101
-0.7% -$15.4K ﹤0.01% 3490
2024
Q2 		$1.28M Sell
163,750
-85,917
-34% -$464K ﹤0.01% 4113
2024
Q1 		$1.03M Sell
249,667
-46,538
-16% -$185K ﹤0.01% 4323
2023
Q4 		$773K Buy
296,205
+82,391
+39% +$169K ﹤0.01% 4508
2023
Q3 		$400K Buy
213,814
+97,399
+84% +$186K ﹤0.01% 4611
2023
Q2 		$292K Buy
116,415
+93,311
+404% +$170K ﹤0.01% 4840
2023
Q1 		$40K Buy
23,104
+9,522
+70% +$26K ﹤0.01% 5785
2022
Q4 		$58K Buy
13,582
+1,190
+10% +$2.17K ﹤0.01% 5572
2022
Q3 		$15K Buy
12,392
+7,257
+141% +$8.21K ﹤0.01% 5879
2022
Q2 		$6K Sell
5,135
-18,849
-79% -$26.4K ﹤0.01% 6128
2022
Q1 		$58K Sell
23,984
-9,503
-28% -$24K ﹤0.01% 5737
2021
Q4 		$90K Buy
33,487
+16,544
+98% +$79.5K ﹤0.01% 5733
2021
Q3 		$85K Sell
16,943
-212
-1% -$1.52K ﹤0.01% 5648
2021
Q2 		$128K Sell
17,155
-7,067
-29% -$46.4K ﹤0.01% 5451
2021
Q1 		$142K Sell
24,222
-469,743
-95% -$3.03M ﹤0.01% 5285
2020
Q4 		$2.32M Sell
493,965
-1,071,121
-68% -$4.54M ﹤0.01% 3374
2020
Q3 		$5.48M Buy
+1,565,086
New +$5.42M ﹤0.01% 2491
2018
Q4 		– Sell
-15,144
Closed -$34K – 5928
2018
Q3 		$34K Buy
+15,144
New +$34.9K ﹤0.01% 5318
2018
Q2 		– Sell
-6,511
Closed -$84K – 5682
2018
Q1 		$84K Buy
6,511
+5,500
+544% +$68.7K ﹤0.01% 4650
2017
Q4 		$11K Buy
+1,011
New +$11.3K ﹤0.01% 5255

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase's SMMT Position: Q2 2026 in Review

JP Morgan Chase increased its Summit Therapeutics (SMMT) stake by 5.6% in Q2 2026, buying an estimated $64.1K and bringing the position to 68,169 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #4624.

JP Morgan Chase first reported a position in SMMT in Q4 2017 and has held it in 27 quarters since. The position peaked at $11.1M in Q1 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • JP Morgan Chase held 68,169 shares of Summit Therapeutics worth $1.07M as of Q2 2026.
  • JP Morgan Chase bought 3,615 Summit Therapeutics shares in Q2 2026, an estimated $64.1K.
  • Summit Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4624 holding.
  • JP Morgan Chase first reported a position in Summit Therapeutics in Q4 2017 and has held it in 27 quarters since.
  • JP Morgan Chase's Summit Therapeutics position peaked at $11.1M in Q1 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.